CTRI/2024/03/063721尚未招募Unknown
on-Interventional Study - Use of lorlatinib in treatment-naïve adult patients with metastatic or locally advanced anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) from India. - NI
Pfizer Products India Private Limited0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •Patients with histologically or cytologically confirmed diagnosis of locally advanced or metastatic (Stage IV) NSCLC with positive ALK-rearrangement
- •No prior systemic treatment for metastatic disease, however up to 2 cycles of chemotherapy are permitted.
排除标准
- •Patients who fail to meet the predefined criteria for inclusion will be excluded from the
研究者
相似试验
招募中
不适用
Evaluation of lorlatinib efficacy of patients with EML4-ALKALK positive lung cancerJPRN-UMIN000042617Japanese Society of Lung Cancer150
进行中（未招募）
1 期
ot applicableCTIS2023-508953-16-00ationwide Childrens Hospital15
进行中（未招募）
不适用
A study of erlotinib (Tarceva®) treatment in patients with locally advanced or metastatic non-small cell lunf cancer who present activating mutations in the tyrosine kinase domain of the epidermal growth factor receptorocally advanced or metastatic non-small cell lung cancer with activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor.MedDRA version: 14.0Level: LLTClassification code 10025054Term: Lung cancer non-small cell stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-023869-21-FIRoche Oy
进行中（未招募）
1 期
Study of Lorlatinib In Participants with Anaplastic Lymphoma Kinase (ALK) -Positive NSCLCALK-positive metastatic non-small-cell lung cancerMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-002504-41-GBPfizer Inc.70
招募中
4 期
Study of Lorlatinib In People With ALK-positive Non-small Cell Lung CancerCTRI/2023/01/049349Pfizer Inc